Artificial intelligence (AI) software company Viz.ai has debuted new cerebral aneurysm detection software at the Society of Vascular and Interventional Neurology (SVIN) 2021 annual meeting in Phoenix.
Viz ANX, which is pending 510(k) clearance from the U.S. Food and Drug Administration (FDA), uses AI to detect aneurysms on CT angiography scans and alert providers to the findings.
Also, the company debuted Viz SDH, a research-only algorithm that supports the EMBOLISE trial, in which researchers are evaluating the safety and efficacy of embolization of the middle meningeal artery using the Medtronic's Onyx liquid embolic system (LES) for the treatment of symptomatic subacute or chronic subdural hematoma.
Viz.ai's algorithm includes volumetric segmentation and measurement of the maximum thickness of the bleed and detects suspected SDH to alert clinicians to patients who might be candidates for the EMBOLISE study.
